title: Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells.
abstract: Arctigenin (Arc) has been shown to act on scopolamine-induced memory deficit mice and to provide a neuroprotective effect on cultured cortical neurons from glutamate-induced neurodegeneration through mechanisms not completely defined. Here, we investigated the neuroprotective effect of Arc on H89-induced cell damage and its potential mechanisms in mouse cortical neurons and human SH-SY5Y neuroblastoma cells. We found that Arc prevented cell viability loss induced by H89 in human SH-SY5Y cells. Moreover, Arc reduced intracellular beta amyloid (Aβ) production induced by H89 in neurons and human SH-SY5Y cells, and Arc also inhibited the presenilin 1(PS1) protein level in neurons. In addition, neural apoptosis in both types of cells, inhibition of neurite outgrowth in human SH-SY5Y cells and reduction of synaptic marker synaptophysin (SYN) expression in neurons were also observed after H89 exposure. All these effects induced by H89 were markedly reversed by Arc treatment. Arc also significantly attenuated downregulation of the phosphorylation of CREB (p-CREB) induced by H89, which may contribute to the neuroprotective effects of Arc. These results demonstrated that Arc exerted the ability to protect neurons and SH-SY5Y cells against H89-induced cell injury via upregulation of p-CREB.
authors.affiliation: School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, Liaoning, China.
authors.forename: Nan
authors.initials: N
authors.lastname: Zhang
authors.forename: Qingping
authors.initials: Q
authors.lastname: Wen
authors.forename: Lu
authors.initials: L
authors.lastname: Ren
authors.forename: Wenbo
authors.initials: W
authors.lastname: Liang
authors.forename: Yang
authors.initials: Y
authors.lastname: Xia
authors.forename: Xiaodan
authors.initials: X
authors.lastname: Zhang
authors.forename: Dan
authors.initials: D
authors.lastname: Zhao
authors.forename: Dong
authors.initials: D
authors.lastname: Sun
authors.forename: Yv
authors.initials: Y
authors.lastname: Hu
authors.forename: Haiguang
authors.initials: H
authors.lastname: Hao
authors.forename: Yaping
authors.initials: Y
authors.lastname: Yan
authors.forename: Guangxian
authors.initials: G
authors.lastname: Zhang
authors.forename: Jingxian
authors.initials: J
authors.lastname: Yang
authors.forename: Tingguo
authors.initials: T
authors.lastname: Kang
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism*; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D017705:Lignans / Q000494:pharmacology*; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D017362:Cyclic AMP Response Element-Binding Protein; D005663:Furans; D017705:Lignans; D018696:Neuroprotective Agents; C071942:arctigenin
references.citation: Biol Pharm Bull. 2010;33(11):1847-53
references.pmid: 21048310
references.citation: Neuropharmacology. 2008 Apr;54(5):845-53
references.pmid: 18291427
references.citation: Neurology. 2006 Jan 24;66(2 Suppl 1):S69-73
references.pmid: 16432149
references.citation: J Neurochem. 2012 Jul;122(1):58-71
references.pmid: 22533963
references.citation: J Neurophysiol. 2009 May;101(5):2539-49
references.pmid: 19261706
references.citation: Genes Cells. 2011 Nov;16(11):1121-32
references.pmid: 21988724
references.citation: J Neurosci. 2001 Jun 15;21(12):4125-33
references.pmid: 11404397
references.citation: BMC Neurosci. 2012 May 18;13:48
references.pmid: 22607375
references.citation: J Neurosci. 2006 Jun 14;26(24):6533-42
references.pmid: 16775141
references.citation: PLoS One. 2012;7(4):e35823
references.pmid: 22540007
references.citation: Neuropharmacology. 2010 May;58(6):911-20
references.pmid: 19917299
references.citation: J Mol Cell Cardiol. 2004 Nov;37(5):1001-11
references.pmid: 15522277
references.citation: Annu Rev Biochem. 1999;68:821-61
references.pmid: 10872467
references.citation: Biochem Pharmacol. 2012 Aug 15;84(4):468-76
references.pmid: 22687625
references.citation: Ann Neurol. 2011 Jan;69(1):34-46
references.pmid: 21280074
references.citation: Annu Rev Neurosci. 1998;21:127-48
references.pmid: 9530494
references.citation: Mol Neurodegener. 2011 Aug 19;6:60
references.pmid: 21854604
references.citation: Chin Med. 2011 Mar 25;6(1):12
references.pmid: 21435270
references.citation: Neuroscience. 2002;115(4):1221-9
references.pmid: 12453493
references.citation: J Neurosci. 2011 Jun 29;31(26):9735-45
references.pmid: 21715638
references.citation: Surgery. 2003 Aug;134(2):197-205
references.pmid: 12947318
references.citation: J Biol Chem. 2011 Nov 11;286(45):38825-32
references.pmid: 21965666
references.citation: Biol Pharm Bull. 2011;34(2):290-4
references.pmid: 21415543
references.citation: Inflamm Res. 2009 Dec;58(12):863-72
references.pmid: 19547917
references.citation: Planta Med. 2011 Sep;77(13):1525-7
references.pmid: 21308615
references.citation: Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6321-8
references.pmid: 20671279
references.citation: Cell Signal. 2005 Nov;17(11):1343-51
references.pmid: 16125054
references.citation: Neuron. 2002 Aug 15;35(4):605-23
references.pmid: 12194863
references.citation: Free Radic Res. 2002 Dec;36(12):1307-13
references.pmid: 12607822
references.citation: Neuroscience. 2012 Dec 13;226:388-96
references.pmid: 23000625
references.citation: PLoS One. 2011;6(11):e28280
references.pmid: 22140566
references.citation: J Neurosci Res. 2002 Apr 15;68(2):233-40
references.pmid: 11948668
references.citation: Diabetes. 2006 Aug;55(8):2220-30
references.pmid: 16873684